Table 1. Primary and Secondary Outcomes of Intravitreal Bevacizumab Injection at Baseline and One Month after Injection. Data Are Expressed as Mean ± SD.
| Variables | Baseline | 1 month | 95% CI of difference | P-value |
| Plasma VEGF level (pg/mL) | 345.3 ± 239.6 | 162.7 ± 161.4 | −227.5 to −137.7 | <0.001* |
| UACR (mg/g) | 372 ± 622 | 378 ± 605 | −70 to 83 | 0.96 |
| SCr (mg/dL) | 0.97 ± 0.27 | 0.98 ± 0.25 | −0.03 to 0.05 | 0.63 |
| eGFR (mL/min/1.73 m2) | 71.3 ± 18.6 | 70.4 ± 18.6 | −3.7 to 1.8 | 0.52 |
| Systolic BP (mm Hg) | 135 ± 12 | 136 ± 14 | −1 to 3 | 0.21 |
| Diastolic BP (mm Hg) | 77 ± 10 | 82 ± 8 | 2 to 8 | 0.002* |
| Platelet (cells/mm3) | 271250 ± 67699 | 244000 ± 70584 | −42618 to −11882 | <0.001* |
| Hb (g/dL) | 12.38 ± 1.48 | 12.59 ± 1.43 | 0.01 to 0.42 | 0.04* |
| WBC (cells/mm3) | 7485 ± 1746 | 7508 ± 1828 | −334 to 379 | 0.90 |
BP: blood pressure, eGFR: estimated glomerular filtration rate, Hb: hemoglobin, SCr: serum creatinine, UACR: urinary albumin-to-creatinine ratio, VEGF: vascular endothelial growth factor, WBC: white blood cell, CI: confidence interval
* Significant